BMS-265246

Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. BMS-265246 is a cell-permeable inhibitor of Cdk1/cyclin B and Cdk2/cyclin E (IC50s = 6 and 9 nM, respectively). It less potently inhibits Cdk4/cyclin D (IC50 = 0.23 µM). BMS-265246 blocks the cycling of HCT116 cells (EC50 = 0.29-0.49 µM), resulting in cell cycle arrest in G2 phase.Formal Name: (4-butoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)(2,6-difluoro-4-methylphenyl)-methanone. CAS Number: 582315-72-8. Molecular Formula: C18H17F2N3O2. Formula Weight: 345.3. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 10 mg/ml, DMF:PBS(pH7.2) (1:2): 0.3 mg/ml, DMSO: 5 mg/ml. lambdamax: 210, 245, 291 nm. SMILES: CC1=CC(F)=C(C(C2=C(OCCCC)C(C=NN3)=C3N=C2)=O)C(F)=C1. InChi Code: InChI=1S/C18H17F2N3O2/c1-3-4-5-25-17-11(8-21-18-12(17)9-22-23-18)16(24)15-13(19)6-10(2)7-14(15)20/h6-9H,3-5H2,1-2H3,(H,21,22,23). InChi Key: SCFMWQIQBVZOQR-UHFFFAOYSA-N.